Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹⁻³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and achieve global health equity.
Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty.
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers.
Hot Spot Presentations Building evidence and confidence in Liquid Biopsy solutions 9 September...
Discover how a deep learning algorithm, GIInger™, leverages low-coverage sequencing data to identify homologous recombination deficiency (HRD)-induced genomic instability.
We’re often asked how we avoid overfitting when developing predictive machine learning models for clinical research. This technical note explains how.
Liquid biopsy is revolutionizing precision oncology with a non-invasive approach to tumor profiling. In this blog, we explore its clinical applications and why the right analytical technologies are needed when searching in a sea of genomic data.
SOPHiA GENETICS™ is excited to participate in the "9ème congrès de la SFMPP" taking place...
Deep learning-based approaches to genomic instability assessment can help overcome the limitations of current methods and maximize insights from tumor samples.
Lymphoid neoplasms encompassing lymphomas and some leukemia like Chronic Lymphocytic Leukaemia...
In this Spotlight session, Dr.Elena Repetti, Chief of Medical Genetics of TomaLab in Italy shares with us TomaLab’s mission in healthcare, their experience using SOPHiA GENETICS’s solutions as well as the company’s vision for the future and the partnership with SOPHiA GENETICS.
SOPHiA GENETICS™ is excited to be a part of the Association for Molecular Pathology (AMP) 2023...
